|
2019 Conference Publication Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancerRaninga, P., Lee, A., Sinha, D., Shin, Y-Y., Mittal, D., Kalimutho, M. and Khanna, K. K. (2019). Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press. |
|
2018 Conference Publication CEP55 over-expression causes genomic instability to initiate spontaneous tumour formation in vivoSinha, D., Kalimutho, M., Bain, A.L. and Khanna, K.K. (2018). CEP55 over-expression causes genomic instability to initiate spontaneous tumour formation in vivo. 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, Netherlands, 30 June – 3 July 2018. London, United Kingdom: Elsevier. doi: 10.1136/esmoopen-2018-eacr25.730 |
|
2017 Conference Publication Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancerSinha, D., Kalimutho, M., Lopez, A. J. and Khanna, K. K. (2017). Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8-12 September 2017. Oxford, United Kingdom: OXFORD UNIV. |
|
2017 Conference Publication Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancerRaninga, P., Kalimutho, M., Sinha, D., Bain, A., Tonissen, K. and Khanna, K. K. (2017). Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer. 42nd European Society for Medical Oncology Congress (ESMO), Madrid, Spain, 8-12 September 2017. Oxford, United Kingdom: Oxford University Press. |
|
2017 Conference Publication Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expressionSinha, Debottam, Kalimutho, Murugan, Lopez, J. Alejandro and Khanna, Kum Kum (2017). Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expression. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC , United States, 1-5 April 2017. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2017-1144 |
|
2017 Conference Publication Abstract PR04: Wnt and MAPK pathway activation in conventional and serrated colorectal neoplasiaWhitehall, Vicki, Borowsky, Jennifer, Bond, Catherine, Bettington, Mark, Pearson, Sally-Ann, Kalimutho, Murugan, Liu, John, Dumenil, Troy, McKeone, Diane, Jamieson, Saara, Fernando, Winnie, Fennell, Lochlan, Clouston, Andrew, Rosty, Christophe, Brown, Ian, Walker, Neal and Leggett, Barbara (2017). Abstract PR04: Wnt and MAPK pathway activation in conventional and serrated colorectal neoplasia. AACR Special Conference: Colorectal Cancer: From Initiation to Outcomes, Tampa, FL, United States, 17-20 September 2016. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/1538-7445.crc16-pr04 |
|
2015 Conference Publication Effects of the porcupine inhibitor, LGK974, on RNF43 mutant and wild type colorectal cancer cell linesBond, C., Kalimutho, M., Bettington, M., Pearson, S., Leggett, B. and Whitehall, V. (2015). Effects of the porcupine inhibitor, LGK974, on RNF43 mutant and wild type colorectal cancer cell lines. Abstracts of Gastro 2015 GESA‐AGW and WGO International Congress, Gastroenterological Society of Australia Australian Gastroenterology Week 2015 | World Congress of Gastroenterology, Brisbane, QLD, Australia, 28 September‐2 October 2015. Richmond, VIC, Australia: John Wiley & Sons. |
